Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious
health problems worldwide. These two diseases have similar pathological spectra, ranging …

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the
expression of genes responsible for energy metabolism, cellular development, and …

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic
syndrome. The underlying causes of the disease progression in NAFLD are unclear. Recent …

There is worldwide epidemic of non-alcoholic fatty liver disease (NAFLD). NAFLD is a
clinical entity related to metabolic syndrome. Majority of the patients are obese but the …

Non-alcoholic fatty liver disease (NAFLD) related to insulin resistance (IR) is a growing
global health concern. Recent studies have indicated that metformin could improve IR and …

OBJECTIVES: Factors that determine disease severity in nonalcoholic fatty liver disease
(NAFLD) are unclear, but exercise is a recommended treatment. We evaluated the …

Aliment Pharmacol Ther 2012; 35: 66–75 Summary Background Thiazolidinediones (TZDs)
have been used in the treatment of non‐alcoholic steatohepatitis (NASH). However, the …

We performed a Bayesian network meta‐analysis combining direct and indirect treatment
comparisons to assess the comparative effectiveness of pharmacological agents for the …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide.
Several lines of evidence have indicated a pathogenic role of insulin resistance, and a …

Non-alcoholic fatty liver disease (NAFLD) is a significant global health burden in children,
adolescents and adults with substantial rise in prevalence over the last decades …